clinical trial · NCT01972711
Study Assessing SEP-363856 in Male and Female Volunteers With High or Low Schizotype Characteristics
Otsuka Pharmaceutical Development & Commercialization, Inc.·phase1·completed·n = 105
SchizophreniaSEP-363856AmisulpridePlacebo
brief summary
This study is designed to evaluate the effects of a single dose of SEP-363856 in healthy male and female volunteers with high or low schizotype characteristics.
started
Mar 1, 2014
primary completion
Jul 1, 2015
completion
Jul 1, 2015
last updated
Jun 26, 2024
detailed description
The study is a randomized, double-blind, placebo-controlled functional magnetic resonance imaging (fMRI) study of the effects of a single dose of SEP-363856 and amisulpride on blood oxygen level dependent (BOLD) signal in healthy male and female volunteers with high or low schizotype characteristics.
official title
A Randomized, Double-blind, Placebo-controlled, Single-dose, Study of the Effects of SEP 363856 and Amisulpride on BOLD-fMRI Signal in Healthy Male and Female Volunteers With High or Low Schizotype Characteristics.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol